GSK’s lung cancer strategy received a fresh data boost tied to its ROS1 pipeline. At the World Conference on Lung Cancer, GSK reported a 94% objective response rate in a predefined TKI-naive cohort from its registrational phase I/II Arros-1 study of jideytro (zidesamtinib) in ROS1-positive NSCLC, supporting plans for a supplemental NDA filing with the U.S. FDA. The result adds incremental clinical evidence for first-line-adjacent positioning in ROS1-positive disease and suggests GSK is moving quickly to extend regulatory conversations. For the sector, the development illustrates how sponsors are using high response rates in defined molecular subgroups to accelerate label-expansion paths in lung cancer, where competitive differentiation hinges on durability and biomarker-selected benefit.